$ADVM
Adverum Biotechnologies, Inc.

2017 Q1 Form 10-K Financial Statement

#000156459017003759 Filed on March 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016 Q3
Revenue $462.0K $488.0K $395.0K
YoY Change 74.34% -49.17% -58.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.990M $4.780M $6.150M
YoY Change -3.97% -10.99% -19.4%
% of Gross Profit
Research & Development $9.061M $7.900M $8.360M
YoY Change 21.46% -4.13% 11.13%
% of Gross Profit
Depreciation & Amortization $520.0K $480.0K $460.0K
YoY Change 62.5% 60.0% 91.67%
% of Gross Profit
Operating Expenses $17.05M $23.88M $14.90M
YoY Change 8.1% 57.71% -1.66%
Operating Profit
YoY Change
Interest Expense $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $489.0K $220.0K $210.0K
YoY Change 321.55% 144.44% 79.49%
Pretax Income -$16.10M -$23.17M -$14.30M
YoY Change 4.61% 64.44% 1.56%
Income Tax -$780.0K
% Of Pretax Income
Net Earnings -$16.10M -$22.39M -$14.30M
YoY Change 4.59% 58.89% 1.54%
Net Earnings / Revenue -3484.63% -4588.93% -3620.51%
Basic Earnings Per Share
Diluted Earnings Per Share -$382.1K -$535.1K -$345.2K
COMMON SHARES
Basic Shares Outstanding 42.06M 41.72M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $209.5M $222.2M $231.3M
YoY Change -15.22% -14.24% -13.98%
Cash & Equivalents $71.57M $222.2M $231.3M
Short-Term Investments $137.9M
Other Short-Term Assets $3.100M $2.200M $2.800M
YoY Change 210.0% 46.67% 86.67%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $212.6M $225.3M $235.9M
YoY Change -14.69% -13.69% -12.75%
LONG-TERM ASSETS
Property, Plant & Equipment $4.100M $4.169M $4.300M
YoY Change 13.89% 30.81% 29.13%
Goodwill
YoY Change
Intangibles $5.000M $5.000M
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $140.0K $140.0K
YoY Change 0.0% 0.0% 1.45%
Total Long-Term Assets $9.329M $9.309M $20.70M
YoY Change 149.84% 179.8% 496.89%
TOTAL ASSETS
Total Short-Term Assets $212.6M $225.3M $235.9M
Total Long-Term Assets $9.329M $9.309M $20.70M
Total Assets $221.9M $234.6M $256.6M
YoY Change -12.26% -11.25% -6.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.383M $1.474M $3.100M
YoY Change 596.09% 143.64% 171.69%
Accrued Expenses $6.600M $6.500M $5.800M
YoY Change 69.23% 62.5% 56.76%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $11.97M $9.896M $10.60M
YoY Change 113.68% 50.53% 63.18%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $370.0K $386.0K $7.700M
YoY Change -93.62% -92.58% 54.0%
Total Long-Term Liabilities $370.0K $386.0K $7.700M
YoY Change -93.62% -92.58% 54.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.97M $9.896M $10.60M
Total Long-Term Liabilities $370.0K $386.0K $7.700M
Total Liabilities $20.55M $18.98M $20.30M
YoY Change 80.75% 61.87% 76.54%
SHAREHOLDERS EQUITY
Retained Earnings -$214.0M -$197.9M
YoY Change 114.96% 135.14%
Common Stock $415.6M $413.5M
YoY Change 21.84% 22.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $201.4M $215.6M $236.2M
YoY Change
Total Liabilities & Shareholders Equity $221.9M $234.6M $256.6M
YoY Change -12.27% -11.25% -6.29%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016 Q3
OPERATING ACTIVITIES
Net Income -$16.10M -$22.39M -$14.30M
YoY Change 4.59% 58.89% 1.54%
Depreciation, Depletion And Amortization $520.0K $480.0K $460.0K
YoY Change 62.5% 60.0% 91.67%
Cash From Operating Activities -$11.82M -$8.350M -$9.640M
YoY Change -2.72% -8.54% 4.56%
INVESTING ACTIVITIES
Capital Expenditures $263.0K -$920.0K -$360.0K
YoY Change 115.57% 384.21% -72.52%
Acquisitions
YoY Change
Other Investing Activities -$138.6M $0.00 $0.00
YoY Change -467.22% -100.0% -100.0%
Cash From Investing Activities -$138.9M -$920.0K -$360.0K
YoY Change -469.09% -103.06% -103.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.0K 210.0K 0.000
YoY Change -26.92% -175.0% -100.0%
NET CHANGE
Cash From Operating Activities -11.82M -8.350M -9.640M
Cash From Investing Activities -138.9M -920.0K -360.0K
Cash From Financing Activities 190.0K 210.0K 0.000
Net Change In Cash -150.5M -9.060M -10.00M
YoY Change -684.84% -143.87% -6766.67%
FREE CASH FLOW
Cash From Operating Activities -$11.82M -$8.350M -$9.640M
Capital Expenditures $263.0K -$920.0K -$360.0K
Free Cash Flow -$12.08M -$7.430M -$9.280M
YoY Change -1.54% -16.89% 17.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42063237
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Trading Symbol
TradingSymbol
ADVM
CY2016 dei Entity Registrant Name
EntityRegistrantName
Adverum Biotechnologies, Inc.
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001501756
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016Q4 us-gaap Liabilities
Liabilities
18983000
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
215600000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
234583000
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016 us-gaap License And Services Revenue
LicenseAndServicesRevenue
1455000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
413518000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197915000
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2016Q4 us-gaap Assets
Assets
234583000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1474000
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2016Q2 dei Entity Public Float
EntityPublicFloat
99800000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
221348000
CY2015Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
37732000
CY2016Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
886000
CY2015Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
449000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2218000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1463000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
225274000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
260992000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4169000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3187000
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5000000
CY2015Q4 us-gaap Assets
Assets
264319000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
605000
CY2016Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
25000
CY2015Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1013000
CY2016Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6451000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
96000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1850000
CY2015Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4706000
CY2016Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
1250000
CY2015 us-gaap License And Services Revenue
LicenseAndServicesRevenue
2319000
CY2014 us-gaap License And Services Revenue
LicenseAndServicesRevenue
572000
CY2016 us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
60714000
CY2015 us-gaap Restructuring Charges
RestructuringCharges
2573000
CY2014 us-gaap Interest Expense
InterestExpense
18000
CY2014 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
759000
CY2014 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-204000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47453000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25404000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-775000
CY2014 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
3230000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-113747000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-47453000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-28634000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-8210000
CY2014 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
2000000
CY2014 advm Adjustments To Additional Paid In Capital Repurchase Of Beneficial Conversion Feature Value
AdjustmentsToAdditionalPaidInCapitalRepurchaseOfBeneficialConversionFeatureValue
2000000
CY2014 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
3230000
CY2014 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
307000
CY2014 advm Stock Issued During Period Value New Issues On Exercise Of Over Allotment Option By Underwriter
StockIssuedDuringPeriodValueNewIssuesOnExerciseOfOverAllotmentOptionByUnderwriter
14229000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8567000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
149483000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
138954000
CY2015 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
218000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11505000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
188000
CY2015 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
145000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7998000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
25462000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16976000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-25404000
CY2016 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
6000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25421000
CY2015 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
-6000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-114522000
CY2015 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-15000
CY2014 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-17000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47474000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.46
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-47453000
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25479000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-113747000
CY2016 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-113743000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.14
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.86
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11651000
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25858722
CY2015Q4 advm Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
4007000
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25858722
CY2015Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
66000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
883000
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9896000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6574000
CY2016Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
352000
CY2015Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
447000
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
7099000
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
386000
CY2015Q4 us-gaap Liabilities
Liabilities
11727000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
336768000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-84168000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
252592000
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
264319000
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41805009
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41805009
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
106453000
CY2014 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2000000
CY2014 us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
4000000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-71000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
531000
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
624000
CY2015 advm Increase Decrease In Deposit And Other Noncurrent Assets
IncreaseDecreaseInDepositAndOtherNoncurrentAssets
3000
CY2014 advm Increase Decrease In Deposit And Other Noncurrent Assets
IncreaseDecreaseInDepositAndOtherNoncurrentAssets
-7000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-111000
CY2015 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-312000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-6000
CY2016 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-190000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
943000
CY2016 us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3449000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
38775000
CY2015 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
724000
CY2014 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2904000
CY2016 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-988000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-41569000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-943000
CY2015 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
427000
CY2016 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
64845000
CY2016 advm Adjustment To Additional Paid In Capital Remeasurement Of Contingent Common Stock Warrant
AdjustmentToAdditionalPaidInCapitalRemeasurementOfContingentCommonStockWarrant
8000
CY2016 advm Adjustments To Additional Paid In Capital Warrant Issued In Connection With Financing Arrangement
AdjustmentsToAdditionalPaidInCapitalWarrantIssuedInConnectionWithFinancingArrangement
26000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11416000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
763000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
186000
CY2016 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
493000
CY2015 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
11099000
CY2014 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2806000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1603000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
812000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
162000
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-21000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
11416000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
11505000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
8567000
CY2016 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8000
CY2015 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
218000
CY2014 advm Non Cash Interest Expense
NonCashInterestExpense
18000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-780000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
437000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8000
CY2015 us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
1013000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3360000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2313000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
7459000
CY2016 us-gaap Straight Line Rent
StraightLineRent
65000
CY2015 us-gaap Straight Line Rent
StraightLineRent
-207000
CY2014 us-gaap Straight Line Rent
StraightLineRent
-298000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-38366000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-35338000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-5648000
CY2015 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
88427000
CY2016 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
37738000
CY2015 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
49850000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2412000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2992000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
138954000
CY2014 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
606000
CY2016 advm Fixed Assets In Accounts Payable And Current Liabilities
FixedAssetsInAccountsPayableAndCurrentLiabilities
180000
CY2015 advm Fixed Assets In Accounts Payable And Current Liabilities
FixedAssetsInAccountsPayableAndCurrentLiabilities
178000
CY2014 advm Fixed Assets In Accounts Payable And Current Liabilities
FixedAssetsInAccountsPayableAndCurrentLiabilities
235000
CY2014 advm Deferred Offering Costs Accrued Expenses
DeferredOfferingCostsAccruedExpenses
379000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
763000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
188000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
18000
CY2016 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
493000
CY2015 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
427000
CY2016 advm Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
186000
CY2015 advm Proceeds From Employee Stock Purchase Plan
ProceedsFromEmployeeStockPurchasePlan
145000
CY2016 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
100000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
556000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
138860000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
165442000
CY2016 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-143000
CY2015 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-9000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-11000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
822000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
61944000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
158840000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159404000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
564000
CY2016 us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
64845000
CY2014 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2000000
CY2014 advm Issuance Of Warrants On Convertible Preferred Stock
IssuanceOfWarrantsOnConvertiblePreferredStock
266000
CY2016 advm Warrants Issued In Connection With Financing And License Agreement
WarrantsIssuedInConnectionWithFinancingAndLicenseAgreement
26000
CY2015 advm Warrants Issued In Connection With Financing And License Agreement
WarrantsIssuedInConnectionWithFinancingAndLicenseAgreement
218000
CY2014 advm Warrants Issued In Connection With Financing And License Agreement
WarrantsIssuedInConnectionWithFinancingAndLicenseAgreement
42000
CY2015Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
230000
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates<font style="font-weight:normal;">&#8212;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. On an ongoing basis, the Company evaluates its estimates and assumptions, including those related to research and development expense accruals, stock-based compensation expense, income taxes, and fair value of common stock warrants. The Company&#8217;s actual results may differ from these estimates under different assumptions or conditions. There have been no significant changes from the Company&#8217;s original estimates in any periods presented.</font></p></div>
CY2016Q4 us-gaap Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1
AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1
0
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6763000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4178000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2594000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
991000
CY2016Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2570000
CY2015Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2047000
CY2016Q4 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
1683000
CY2015Q4 advm Accrued Preclinical Costs
AccruedPreclinicalCosts
642000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
894000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1177000
CY2016Q4 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
1142000
CY2015Q4 advm Accrued Clinical And Development Process Costs
AccruedClinicalAndDevelopmentProcessCosts
101000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
1162000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
1197000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
403000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
3891000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1745000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
162000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
40000
CY2016 us-gaap Lessor Leasing Arrangements Operating Leases Renewal Term
LessorLeasingArrangementsOperatingLeasesRenewalTerm
P4Y
CY2016 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2020-05-08
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
1129000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1525000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
662000
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
0
CY2016 us-gaap Maintenance Costs
MaintenanceCosts
600000
CY2015 us-gaap Maintenance Costs
MaintenanceCosts
100000
CY2016 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
0
CY2016 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
0
CY2016 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2006-07-17
CY2016 dei Entity Information Date To Change Former Legal Or Registered Name
EntityInformationDateToChangeFormerLegalOrRegisteredName
2016-05-11
CY2015Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8300000
CY2016Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
100000
CY2015Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
100000
CY2016 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2016 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.20
CY2015Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
15
CY2015Q4 us-gaap Restructuring Charges
RestructuringCharges
2600000
CY2014Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2015 us-gaap Payments For Restructuring
PaymentsForRestructuring
511000
CY2015 us-gaap Restructuring Reserve Settled Without Cash2
RestructuringReserveSettledWithoutCash2
1049000
CY2015Q4 us-gaap Restructuring Reserve
RestructuringReserve
1013000
CY2016 us-gaap Payments For Restructuring
PaymentsForRestructuring
988000
CY2016Q4 us-gaap Restructuring Reserve
RestructuringReserve
25000
CY2015Q4 advm Cash And Cash Equivalent Amortized Cost
CashAndCashEquivalentAmortizedCost
208588000
CY2015Q4 advm Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2015Q4 advm Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2015Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
208588000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
37738000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
6000
CY2016 us-gaap Held To Maturity Securities Sold Security Realized Gain Loss
HeldToMaturitySecuritiesSoldSecurityRealizedGainLoss
0
CY2016 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2015 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
215916000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
246320000
CY2016 us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0
CY2015Q3 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
3
CY2015Q4 us-gaap Loss Contingency New Claims Filed Number
LossContingencyNewClaimsFiledNumber
1
CY2014Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
10689027
CY2016 us-gaap Debt Instrument Convertible Beneficial Conversion Feature
DebtInstrumentConvertibleBeneficialConversionFeature
2000000
CY2014Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
600000
CY2016Q4 us-gaap Fair Value Assumptions Exercise Price
FairValueAssumptionsExercisePrice
17.00
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P1Y1M6D
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.001
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.70
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.00
CY2016 advm Share Based Compensation Arrangement By Share Based Payment Award Options Difference Between Options Exercise Price And Closing Price Of Common Stock Intrinsic Value Amount
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsDifferenceBetweenOptionsExercisePriceAndClosingPriceOfCommonStockIntrinsicValueAmount
2.90
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7100000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
11200000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15700000
CY2016 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
11416000
CY2015 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
11505000
CY2014 advm Allocated Share Based Compensation Expense And Recoveries
AllocatedShareBasedCompensationExpenseAndRecoveries
8567000
CY2015Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
2400000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Employees Affected
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
4
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.35
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
15.91
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.56
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
11300000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-96498000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47235000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-25006000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-18024000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-218000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-398000
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-38938000
CY2015 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-16134000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8637000
CY2014 advm Income Tax Reconciliation Loss On Extinguishment Of Related Party Convertible Notes
IncomeTaxReconciliationLossOnExtinguishmentOfRelatedPartyConvertibleNotes
69000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
21000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
45000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Research And Development
IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment
85000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1356000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1418000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
161000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
985000
CY2015 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
295000
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
285000
CY2016 us-gaap Income Tax Reconciliation Nondeductible Expense Impairment Losses
IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
16834000
CY2016 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
326000
CY2015 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
910000
CY2014 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
304000
CY2016 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
16062000
CY2015 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15277000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
8349000
CY2014 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-8000
CY2016 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
3231000
CY2015 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
9000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15785000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19889000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8526000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
3071000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
2681000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
222000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3848000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4328000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3032000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
574000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1945000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
659000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
54000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
68000
CY2015Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
45000
CY2014Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
24000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
24000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23400000
CY2015Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
28888000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
12487000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23400000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
28839000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
12457000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
49000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
30000
CY2015Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
49000
CY2014Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
30000
CY2016Q4 us-gaap Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
1250000
CY2015Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
49000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
30000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2014Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-5400000
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
16400000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9900000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2157000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1568000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
471000
CY2016Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
43000
CY2015 advm Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
172000
CY2014 advm Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
272000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
589000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
925000
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
156000
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2015Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2015 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8548000
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6166000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4932000
CY2016Q1 us-gaap Revenues
Revenues
265000
CY2016Q2 us-gaap Revenues
Revenues
307000
CY2016Q3 us-gaap Revenues
Revenues
395000
CY2016Q4 us-gaap Revenues
Revenues
488000
CY2016Q1 us-gaap Operating Expenses
OperatingExpenses
15773000
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
62189000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
14902000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
23875000
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-15392000
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-61660000
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-14301000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-22394000
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.57
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.76
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.35
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.54
CY2015Q1 us-gaap Revenues
Revenues
203000
CY2015Q2 us-gaap Revenues
Revenues
203000
CY2015Q3 us-gaap Revenues
Revenues
953000
CY2015Q4 us-gaap Revenues
Revenues
960000
CY2015Q1 us-gaap Operating Expenses
OperatingExpenses
9764000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
10085000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
15154000
CY2015Q4 us-gaap Operating Expenses
OperatingExpenses
15139000
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-9509000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-9766000
CY2015Q3 us-gaap Net Income Loss
NetIncomeLoss
-14084000
CY2015Q4 us-gaap Net Income Loss
NetIncomeLoss
-14094000
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2015Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.55
CY2016Q2 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
49100000
CY2016Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
400000
CY2016Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
2200000
CY2016 advm Collaboration Agreement Extension Description
CollaborationAgreementExtensionDescription
On February 23, 2017, Regeneron notified us that, pursuant to Section 2.3 of the collaboration agreement, it is extending the research term of the Collaboration Agreement for an additional three years, through May 1, 2020.

Files In Submission

Name View Source Status
0001564590-17-003759-index-headers.html Edgar Link pending
0001564590-17-003759-index.html Edgar Link pending
0001564590-17-003759.txt Edgar Link pending
0001564590-17-003759-xbrl.zip Edgar Link pending
advm-10k_20161231.htm Edgar Link pending
advm-20161231.xml Edgar Link completed
advm-20161231.xsd Edgar Link pending
advm-20161231_cal.xml Edgar Link unprocessable
advm-20161231_def.xml Edgar Link unprocessable
advm-20161231_lab.xml Edgar Link unprocessable
advm-20161231_pre.xml Edgar Link unprocessable
advm-ex1039_747.htm Edgar Link pending
advm-ex1040_748.htm Edgar Link pending
advm-ex211_145.htm Edgar Link pending
advm-ex231_146.htm Edgar Link pending
advm-ex311_142.htm Edgar Link pending
advm-ex312_143.htm Edgar Link pending
advm-ex31_910.htm Edgar Link pending
advm-ex321_144.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2017030823252018429620.jpg Edgar Link pending
g2017030823252034629621.jpg Edgar Link pending
g2017030823253809729621.jpg Edgar Link pending
g2017030823254021429622.jpg Edgar Link pending
g2017030823255242529623.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending